{"timestamp": "2026-01-18T18:40:21.879299", "question": "{}", "final_output": "Final Assessment:\nWidely metastatic presumed gynecologic malignancy with liver, presacral, bone, and peritoneal disease and severe anemia; primary histology, prior treatments, and current stage/line remain uncertain, so only diagnostic and supportive steps are appropriate today [@2022-12-29|MR; @2022-12-29|CT; @20230103|5600862].\n\nCore Treatment Strategy:\n- Urgently retrieve all prior surgical/biopsy pathology and reports to establish primary site, histologic subtype, grade, and stage; currently unknown.  \n- If prior pathology unobtainable, plan image‑guided biopsy of an accessible metastatic lesion after restaging to secure diagnosis and IHC.  \n- Arrange updated whole‑body staging (contrast CT/MR ± FDG PET/CT) to reassess liver, presacral, bone, peritoneal, and rectal involvement before therapy [@2022-12-29|MR; @2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|11].  \n- Optimize severe anemia with full work‑up and supportive treatment to ensure future systemic‑therapy fitness; repeat CBC and chemistries for baseline [@20230103|5600862].  \n\nChange Triggers:\n- If pathology confirms epithelial ovarian primary and imaging shows widespread metastatic disease, MDT to define systemic treatment intent and palliative focus [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n- If restaging reveals complications (obstruction, impending fracture, spinal/pelvic instability), prioritize urgent surgical/radiation/palliative interventions before systemic therapy planning.", "initial_ops": {"chair": "- Advanced recurrent ovarian malignancy with progressive pelvic mass, pelvic bone lesion, and liver metastases on recent imaging [@2022-12-29|MR; @2022-12-29|CT].  \n- HRD-/BRCA‑wildtype; systemic therapy plan should not assume PARP benefit outside trial; consider standard chemotherapy-based approach [@OH2203828].  \n- Profound anemia (HGB 74 g/L) likely requires optimization and transfusion planning before intensive systemic therapy [@20230103|2023-01-03].  \n- Tumor markers very elevated (CA125, CA19-9, CA15-3); can be used for response monitoring, not for standalone decisions [@20221229|9703212].  \n- Missing: current histology/grade, prior surgery/chemo details, performance status, symptoms, patient goals—must be updated before definitive systemic/locoregional plan.", "oncologist": "- Tumor type, stage, prior surgery/chemotherapy, and current disease status are unknown/needs update to define treatment line and intent.  \n\n- Markedly elevated CA125, CA19-9, CA15-3 and ROMA suggest ovarian malignancy, but histology/pathology report is unknown/needs update [@20221229|9703212].  \n\n- HRD negative and no BRCA1/2 pathogenic variants; this limits certain maintenance options after platinum response [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|18].  \n\n- Significant anemia (Hgb 74 g/L) requires evaluation of cause and correction before or during systemic therapy [@20230103|5600862].  \n\n- Renal and hepatic function appear adequate for most systemic options, but full current labs and trends are unknown/needs update [@20221229|8300002].", "radiologist": "- Presacral pelvic mass enlarged to 53×44 mm with heterogeneous signal and involvement of adjacent peritoneum and sacrum, suspicious recurrence.[@2022-12-29|MR]\n\n- New enhancing nodule in right ilium, concerning for osseous metastasis.[@2022-12-29|MR]\n\n- Multiple enhancing mesenteric/pelvic nodules unchanged, compatible with peritoneal metastases.[@2022-12-29|MR]\n\n- Focal rectal wall thickening with enhancement; needs correlation for invasion versus inflammatory change.[@2022-12-29|MR]\n\n- Liver with multiple new/enlarging hypodense lesions, consistent with progressive hepatic metastases; additional stable hepatic cysts and possible splenic infarct.[@2022-12-29|CT]", "pathologist": "- Only confirmed finding: germline ATM exon8 c.A947G:p.Y316C variant; clinical significance not specified in report [@OH2203828|2022-04-18].  \n- HRD reported negative; no pathogenic germline/somatic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 detected [@OH2203828|2022-04-18].  \n- Underlying tumor type, primary site, histologic subtype, grade, and stage are completely unknown/need update.  \n- No tumor tissue NGS, MSI/MMR, TMB, or other somatic profiling data available/needs update for integrated pathology assessment.  \n- Need full surgical pathology report(s) and any IHC panels to clarify diagnosis and guide biomarker interpretation.", "nuclear": "- No PET/CT or other nuclear imaging available for this visit; metabolic status of pelvic, hepatic, bone lesions unknown/needs update.  \n\n- Prior MR pelvis shows enlarging presacral mass with sacrum, peritoneum, right ilium involvement; recurrence/metastasis structurally suspected [@2022-12-29|MR].  \n\n- Prior CT abdomen shows multiple enlarging hepatic lesions consistent with metastases; PET would better characterize whole-body disease burden [@2022-12-29|CT].  \n\n- For current decision-making, a whole-body FDG PET/CT is needed to assess metabolic activity and refine staging/recurrence mapping.  \n\n- Cannot yet determine if PET would upstage or downstage compared with prior MR/CT; requires new PET/CT acquisition and report."}, "merged_summary": "Key Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n[R2T2 DELTA] chair->oncologist(safety): Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed. | chair->pathologist(missing): Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained. | oncologist->chair(safety): Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.", "final_round_ops": {"Round 1": {"chair": "- Defer definitive systemic/locoregional plan until original pathology (subtype, grade, IHC) is obtained and reviewed [@OH2203828].  \n- Arrange whole-body FDG PET/CT or updated cross-sectional imaging to restage liver, presacral, bone, and possible rectal disease before decisions [@2022-12-29|CT; @2022-12-29|MR].  \n- Optimize marked anemia (Hgb 74 g/L) and repeat full labs to ensure fitness for future systemic therapy [@20230103|2023-01-03].  \n- Collect complete oncologic history, ECOG, symptom burden, comorbidities, and goals of care to define treatment intent and intensity (palliation vs disease control) — currently unknown.  \n- After data completion, reconvene MDT to select appropriate systemic approach and consider targeted trials based on updated imaging and molecular profiling (MSI/MMR/TMB/NGS) — currently unknown.", "oncologist": "- Defer systemic treatment choice until updated post-12/2022 imaging (CT/MR and/or PET/CT) confirms current disease extent; prior reports unknown/needs update.  \n\n- Urgently retrieve and review original surgical/biopsy pathology with histology, grade, stage, and IHC to guide regimen selection; currently unknown.  \n\n- Compile full oncologic history (all prior surgeries, regimens, responses, toxicities, timing of relapse) and current ECOG, symptoms, and goals of care; unknown.  \n\n- Evaluate and manage severe anemia (Hgb 74 g/L) before/during any chemotherapy; complete iron/B12/folate/hemolysis/bleeding work-up and transfusion plan [@20230103|5600862].  \n\n- After data completion, define intent (palliation vs disease control) and choose appropriate next-line systemic category plus targeted/trial eligibility based on biomarkers [@OH2203828|2022-04-18].", "radiologist": "- No imaging newer than 2022-12-29 MR/CT is available; updated whole-body FDG PET/CT restaging is required before planning.[@2022-12-29|MR][@2022-12-29|CT]\n\n- If PET/CT cannot fully characterize local anatomy, consider complementary pelvic MR or contrast CT to assess rectal and sacral involvement.[@2022-12-29|MR]\n\n- Radiology to confirm absence/presence of any post-12/2022 imaging and flag if interval complications (obstruction, fracture, thrombosis) are seen; currently unknown.\n\n- After new imaging, radiology will re-document measurable disease (presacral mass, liver, peritoneum, bone) to support response assessment and palliation planning.[@2022-12-29|MR][@2022-12-29|CT]\n\n- Until restaging completed, avoid definitive local procedures based solely on 12/2022 scans, given possible interval progression or new sites.[@2022-12-29|MR][@2022-12-29|CT]", "pathologist": "- Retrieve and summarize original surgical/biopsy pathology, including primary site, histologic subtype, grade, and key IHC; currently unknown.  \n- Confirm and review any imaging after 12/2022; if absent, obtain whole‑body FDG PET/CT for up‑to‑date staging (bone, rectum, liver).  \n- Defer decisions on treatment line and intent until updated imaging and full pathology are available, per chair safety concern.  \n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) on available blocks once primary and subtype are confirmed; currently unknown.  \n- Reconvene MDT after completing pathology retrieval, updated staging, and basic lab/clinical status review (anemia work‑up, organ function, ECOG).", "nuclear": "- Confirm and review any imaging newer than 12/29/2022; if absent, obtain updated contrast CT/MR plus whole-body FDG PET/CT [@2022-12-29|MR; @2022-12-29|CT].  \n- Use PET/CT to define metabolic extent of presacral mass, sacrum/ilium, peritoneum, liver, and possible rectal invasion [@2022-12-29|MR; @2022-12-29|CT].  \n- Retrieve complete original pathology (site, subtype, grade, IHC) to confirm primary ovarian origin and refine prognosis; currently unknown.  \n- Optimize anemia and overall medical status in parallel, ensuring patient is fit for subsequent systemic and/or locoregional interventions; lab details beyond Hgb unknown.  \n- Reconvene MDT after updated imaging and pathology to finalize staging, recurrence assessment, and integrate PET findings into overall management intent."}, "Round 2": {"chair": "- Urgently retrieve prior pathology or arrange new biopsy to establish primary site, histologic subtype, and grade (currently unknown).  \n- Obtain all post‑12/29/2022 imaging or perform comprehensive restaging (CT/MR ± PET/CT) to reassess liver, bone, presacral, rectal disease [@2022-12-29|CT; @2022-12-29|MR].  \n- Optimize severe anemia (Hgb 74 g/L) and repeat full labs to ensure systemic‑therapy fitness [@20230103|2023-01-03].  \n- Collect detailed treatment history, ECOG, symptoms, comorbidities, and goals to define intent (palliation vs disease control) — currently unknown.  \n- Until pathology and restaging are available, discuss only provisional systemic/locoregional options and avoid committing to specific regimens or trial pathways.", "oncologist": "- Defer commitment to specific regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed; histology currently unknown.  \n\n- Urgently obtain full pathology (primary site, subtype, grade, IHC) or arrange new biopsy if records unobtainable; currently missing.  \n\n- Acquire all post‑12/2022 imaging or arrange whole‑body PET/CT plus targeted CT/MR to restage disease and clarify rectal involvement; missing.  \n\n- Optimize severe anemia (Hgb 74 g/L) with full work‑up and transfusion/other support before systemic therapy decisions [@20230103|2023-01-03].  \n\n- In parallel, document prior treatments, ECOG, symptoms, comorbidities, and goals to define intent (disease control vs palliation) once data complete.", "radiologist": "- 12/29/2022 MR: Presacral mass ~53×44 mm, invading adjacent peritoneum and sacrum; rectal wall thickening/enhancement suggests possible invasion.[@2022-12-29|MR]\n\n- 12/29/2022 MR: New enhancing nodule in right iliac bone, suspicious for osseous metastasis.[@2022-12-29|MR]\n\n- 12/29/2022 MR: Multiple enhancing pelvic mesenteric nodules compatible with peritoneal metastases.[@2022-12-29|MR]\n\n- 12/29/2022 CT: Multiple liver metastases, increased in number and size; largest ~17×14 mm.[@2022-12-29|CT]\n\n- No post-12/29/2022 imaging available; updated whole-body staging (PET/CT ± targeted MR/CT) is needed to guide current decisions.[@2022-12-29|MR][@2022-12-29|CT]", "pathologist": "- Urgently obtain original surgical/biopsy pathology (reports and blocks) to confirm primary site, histologic subtype, grade, and stage; currently unknown.  \n- If outside pathology truly unobtainable, arrange new image‑guided biopsy of accessible lesion for full histology and IHC; currently unknown.  \n- With confirmed subtype, consider tumor profiling (MSI/MMR, TMB ± extended NGS) on available tissue for future options; currently unknown.  \n- Correlate pathology with updated cross‑sectional imaging or PET/CT to clarify rectal involvement and dominant disease sites; post‑12/2022 imaging unknown.  \n- Defer labeling line of therapy or specific systemic strategy until histology/subtype are established and MDT re‑reviews integrated findings.", "nuclear": "- Arrange whole-body FDG PET/CT to update staging beyond 12/2022 CT/MR, including bone and rectal involvement assessment [@2022-12-29|MR; @2022-12-29|CT].  \n- Use PET/CT to confirm metabolic activity of presacral mass, sacral/iliac lesions, peritoneal nodules, and liver metastases [@2022-12-29|MR; @2022-12-29|CT].  \n- Correlate PET/CT with pelvic MR to better distinguish rectal invasion from inflammatory thickening before considering local interventions [@2022-12-29|MR].  \n- Integrate PET findings with tumor marker trends and future imaging for monitoring disease burden and response; current post-12/2022 imaging unknown.  \n- Re-discuss at MDT once PET/CT and pathology are available to align metabolic staging with final intent and palliation planning."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before committing to a new regimen, we must clarify prior systemic lines, ECOG status, and urgent anemia optimization/plan; otherwise treatment intensity and intent are unsafe to define.", "radiologist": null, "pathologist": null, "nuclear": "Given new bone and progressive liver disease, please comment whether PET/CT would materially change management versus proceeding on current MR/CT."}, "oncologist": {"chair": "Systemic regimen choice is impossible today without prior treatment history, performance status, and pathology details; these must be collected before committing to next-line therapy.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": "Given new bone and progressive visceral disease, please advise whether PET/CT adds actionable value over recent MR/CT for systemic-planning and potential local palliation decisions."}, "radiologist": {"chair": null, "oncologist": "No imaging newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions.", "radiologist": null, "pathologist": null, "nuclear": "If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement."}, "pathologist": {"chair": "Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans.", "radiologist": "Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe.", "radiologist": "Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT.", "pathologist": "Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.", "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed.", "radiologist": null, "pathologist": "Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained.", "nuclear": null}, "oncologist": {"chair": "Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Advanced recurrent ovarian malignancy with progressive pelvic mass, pelvic bone lesion, and liver metastases on recent imaging [@2022-12-29|MR; @2022-12-29|CT].  \n- HRD-/BRCA‑wildtype; systemic therapy plan should not assume PARP benefit outside trial; consider standard chemotherapy-based approach [@OH2203828].  \n- Profound anemia (HGB 74 g/L) likely requires optimization and transfusion planning before intensive systemic therapy [@20230103|2023-01-03].  \n- Tumor markers very elevated (CA125, CA19-9, CA15-3); can be used for response monitoring, not for standalone decisions [@20221229|9703212].  \n- Missing: current histology/grade, prior surgery/chemo details, performance status, symptoms, patient goals—must be updated before definitive systemic/locoregional plan.", "timestamp": "2026-01-18T18:37:25.365973"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before committing to a new regimen, we must clarify prior systemic lines, ECOG status, and urgent anemia optimization/plan; otherwise treatment intensity and intent are unsafe to define.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Given new bone and progressive liver disease, please comment whether PET/CT would materially change management versus proceeding on current MR/CT.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:37:50.267326"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:38:00.907899"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n[R1T2 DELTA] chair->oncologist(safety): Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe. | chair->radiologist(missing): Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT. | chair->pathologist(missing): Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Defer definitive systemic/locoregional plan until original pathology (subtype, grade, IHC) is obtained and reviewed [@OH2203828].  \n- Arrange whole-body FDG PET/CT or updated cross-sectional imaging to restage liver, presacral, bone, and possible rectal disease before decisions [@2022-12-29|CT; @2022-12-29|MR].  \n- Optimize marked anemia (Hgb 74 g/L) and repeat full labs to ensure fitness for future systemic therapy [@20230103|2023-01-03].  \n- Collect complete oncologic history, ECOG, symptom burden, comorbidities, and goals of care to define treatment intent and intensity (palliation vs disease control) — currently unknown.  \n- After data completion, reconvene MDT to select appropriate systemic approach and consider targeted trials based on updated imaging and molecular profiling (MSI/MMR/TMB/NGS) — currently unknown.", "timestamp": "2026-01-18T18:38:09.860517"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:39:00.302377"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed.\",\"why\":\"safety\"},{\"target\":\"pathologist\",\"message\":\"Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:39:08.984376"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n[R2T2 DELTA] chair->oncologist(safety): Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed. | chair->pathologist(missing): Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained. | oncologist->chair(safety): Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Urgently retrieve prior pathology or arrange new biopsy to establish primary site, histologic subtype, and grade (currently unknown).  \n- Obtain all post‑12/29/2022 imaging or perform comprehensive restaging (CT/MR ± PET/CT) to reassess liver, bone, presacral, rectal disease [@2022-12-29|CT; @2022-12-29|MR].  \n- Optimize severe anemia (Hgb 74 g/L) and repeat full labs to ensure systemic‑therapy fitness [@20230103|2023-01-03].  \n- Collect detailed treatment history, ECOG, symptoms, comorbidities, and goals to define intent (palliation vs disease control) — currently unknown.  \n- Until pathology and restaging are available, discuss only provisional systemic/locoregional options and avoid committing to specific regimens or trial pathways.", "timestamp": "2026-01-18T18:40:06.811198"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id|page] or [@pubmed:PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Defer definitive systemic/locoregional plan until original pathology (subtype, grade, IHC) is obtained and reviewed [@OH2203828].  \\n- Arrange whole-body FDG PET/CT or updated cross-sectional imaging to restage liver, presacral, bone, and possible rectal disease before decisions [@2022-12-29|CT; @2022-12-29|MR].  \\n- Optimize marked anemia (Hgb 74 g/L) and repeat full labs to ensure fitness for future systemic therapy [@20230103|2023-01-03].  \\n- Collect complete oncologic history, ECOG, symptom burden, comorbidities, and goals of care to define treatment intent and intensity (palliation vs disease control) — currently unknown.  \\n- After data completion, reconvene MDT to select appropriate systemic approach and consider targeted trials based on updated imaging and molecular profiling (MSI/MMR/TMB/NGS) — currently unknown.\",\n    \"oncologist\": \"- Defer systemic treatment choice until updated post-12/2022 imaging (CT/MR and/or PET/CT) confirms current disease extent; prior reports unknown/needs update.  \\n\\n- Urgently retrieve and review original surgical/biopsy pathology with histology, grade, stage, and IHC to guide regimen selection; currently unknown.  \\n\\n- Compile full oncologic history (all prior surgeries, regimens, responses, toxicities, timing of relapse) and current ECOG, symptoms, and goals of care; unknown.  \\n\\n- Evaluate and manage severe anemia (Hgb 74 g/L) before/during any chemotherapy; complete iron/B12/folate/hemolysis/bleeding work-up and transfusion plan [@20230103|5600862].  \\n\\n- After data completion, define intent (palliation vs disease control) and choose appropriate next-line systemic category plus targeted/trial eligibility based on biomarkers [@OH2203828|2022-04-18].\",\n    \"radiologist\": \"- No imaging newer than 2022-12-29 MR/CT is available; updated whole-body FDG PET/CT restaging is required before planning.[@2022-12-29|MR][@2022-12-29|CT]\\n\\n- If PET/CT cannot fully characterize local anatomy, consider complementary pelvic MR or contrast CT to assess rectal and sacral involvement.[@2022-12-29|MR]\\n\\n- Radiology to confirm absence/presence of any post-12/2022 imaging and flag if interval complications (obstruction, fracture, thrombosis) are seen; currently unknown.\\n\\n- After new imaging, radiology will re-document measurable disease (presacral mass, liver, peritoneum, bone) to support response assessment and palliation planning.[@2022-12-29|MR][@2022-12-29|CT]\\n\\n- Until restaging completed, avoid definitive local procedures based solely on 12/2022 scans, given possible interval progression or new sites.[@2022-12-29|MR][@2022-12-29|CT]\",\n    \"pathologist\": \"- Retrieve and summarize original surgical/biopsy pathology, including primary site, histologic subtype, grade, and key IHC; currently unknown.  \\n- Confirm and review any imaging after 12/2022; if absent, obtain whole‑body FDG PET/CT for up‑to‑date staging (bone, rectum, liver).  \\n- Defer decisions on treatment line and intent until updated imaging and full pathology are available, per chair safety concern.  \\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) on available blocks once primary and subtype are confirmed; currently unknown.  \\n- Reconvene MDT after completing pathology retrieval, updated staging, and basic lab/clinical status review (anemia work‑up, organ function, ECOG).\",\n    \"nuclear\": \"- Confirm and review any imaging newer than 12/29/2022; if absent, obtain updated contrast CT/MR plus whole-body FDG PET/CT [@2022-12-29|MR; @2022-12-29|CT].  \\n- Use PET/CT to define metabolic extent of presacral mass, sacrum/ilium, peritoneum, liver, and possible rectal invasion [@2022-12-29|MR; @2022-12-29|CT].  \\n- Retrieve complete original pathology (site, subtype, grade, IHC) to confirm primary ovarian origin and refine prognosis; currently unknown.  \\n- Optimize anemia and overall medical status in parallel, ensuring patient is fit for subsequent systemic and/or locoregional interventions; lab details beyond Hgb unknown.  \\n- Reconvene MDT after updated imaging and pathology to finalize staging, recurrence assessment, and integrate PET findings into overall management intent.\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Urgently retrieve prior pathology or arrange new biopsy to establish primary site, histologic subtype, and grade (currently unknown).  \\n- Obtain all post‑12/29/2022 imaging or perform comprehensive restaging (CT/MR ± PET/CT) to reassess liver, bone, presacral, rectal disease [@2022-12-29|CT; @2022-12-29|MR].  \\n- Optimize severe anemia (Hgb 74 g/L) and repeat full labs to ensure systemic‑therapy fitness [@20230103|2023-01-03].  \\n- Collect detailed treatment history, ECOG, symptoms, comorbidities, and goals to define intent (palliation vs disease control) — currently unknown.  \\n- Until pathology and restaging are available, discuss only provisional systemic/locoregional options and avoid committing to specific regimens or trial pathways.\",\n    \"oncologist\": \"- Defer commitment to specific regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed; histology currently unknown.  \\n\\n- Urgently obtain full pathology (primary site, subtype, grade, IHC) or arrange new biopsy if records unobtainable; currently missing.  \\n\\n- Acquire all post‑12/2022 imaging or arrange whole‑body PET/CT plus targeted CT/MR to restage disease and clarify rectal involvement; missing.  \\n\\n- Optimize severe anemia (Hgb 74 g/L) with full work‑up and transfusion/other support before systemic therapy decisions [@20230103|2023-01-03].  \\n\\n- In parallel, document prior treatments, ECOG, symptoms, comorbidities, and goals to define intent (disease control vs palliation) once data complete.\",\n    \"radiologist\": \"- 12/29/2022 MR: Presacral mass ~53×44 mm, invading adjacent peritoneum and sacrum; rectal wall thickening/enhancement suggests possible invasion.[@2022-12-29|MR]\\n\\n- 12/29/2022 MR: New enhancing nodule in right iliac bone, suspicious for osseous metastasis.[@2022-12-29|MR]\\n\\n- 12/29/2022 MR: Multiple enhancing pelvic mesenteric nodules compatible with peritoneal metastases.[@2022-12-29|MR]\\n\\n- 12/29/2022 CT: Multiple liver metastases, increased in number and size; largest ~17×14 mm.[@2022-12-29|CT]\\n\\n- No post-12/29/2022 imaging available; updated whole-body staging (PET/CT ± targeted MR/CT) is needed to guide current decisions.[@2022-12-29|MR][@2022-12-29|CT]\",\n    \"pathologist\": \"- Urgently obtain original surgical/biopsy pathology (reports and blocks) to confirm primary site, histologic subtype, grade, and stage; currently unknown.  \\n- If outside pathology truly unobtainable, arrange new image‑guided biopsy of accessible lesion for full histology and IHC; currently unknown.  \\n- With confirmed subtype, consider tumor profiling (MSI/MMR, TMB ± extended NGS) on available tissue for future options; currently unknown.  \\n- Correlate pathology with updated cross‑sectional imaging or PET/CT to clarify rectal involvement and dominant disease sites; post‑12/2022 imaging unknown.  \\n- Defer labeling line of therapy or specific systemic strategy until histology/subtype are established and MDT re‑reviews integrated findings.\",\n    \"nuclear\": \"- Arrange whole-body FDG PET/CT to update staging beyond 12/2022 CT/MR, including bone and rectal involvement assessment [@2022-12-29|MR; @2022-12-29|CT].  \\n- Use PET/CT to confirm metabolic activity of presacral mass, sacral/iliac lesions, peritoneal nodules, and liver metastases [@2022-12-29|MR; @2022-12-29|CT].  \\n- Correlate PET/CT with pelvic MR to better distinguish rectal invasion from inflammatory thickening before considering local interventions [@2022-12-29|MR].  \\n- Integrate PET findings with tumor marker trends and future imaging for monitoring disease burden and response; current post-12/2022 imaging unknown.  \\n- Re-discuss at MDT once PET/CT and pathology are available to align metabolic staging with final intent and palliation planning.\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nWidely metastatic presumed gynecologic malignancy with liver, presacral, bone, and peritoneal disease and severe anemia; primary histology, prior treatments, and current stage/line remain uncertain, so only diagnostic and supportive steps are appropriate today [@2022-12-29|MR; @2022-12-29|CT; @20230103|5600862].\n\nCore Treatment Strategy:\n- Urgently retrieve all prior surgical/biopsy pathology and reports to establish primary site, histologic subtype, grade, and stage; currently unknown.  \n- If prior pathology unobtainable, plan image‑guided biopsy of an accessible metastatic lesion after restaging to secure diagnosis and IHC.  \n- Arrange updated whole‑body staging (contrast CT/MR ± FDG PET/CT) to reassess liver, presacral, bone, peritoneal, and rectal involvement before therapy [@2022-12-29|MR; @2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|11].  \n- Optimize severe anemia with full work‑up and supportive treatment to ensure future systemic‑therapy fitness; repeat CBC and chemistries for baseline [@20230103|5600862].  \n\nChange Triggers:\n- If pathology confirms epithelial ovarian primary and imaging shows widespread metastatic disease, MDT to define systemic treatment intent and palliative focus [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n- If restaging reveals complications (obstruction, impending fracture, spinal/pelvic instability), prioritize urgent surgical/radiation/palliative interventions before systemic therapy planning.", "timestamp": "2026-01-18T18:40:21.878964"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Tumor type, stage, prior surgery/chemotherapy, and current disease status are unknown/needs update to define treatment line and intent.  \n\n- Markedly elevated CA125, CA19-9, CA15-3 and ROMA suggest ovarian malignancy, but histology/pathology report is unknown/needs update [@20221229|9703212].  \n\n- HRD negative and no BRCA1/2 pathogenic variants; this limits certain maintenance options after platinum response [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|18].  \n\n- Significant anemia (Hgb 74 g/L) requires evaluation of cause and correction before or during systemic therapy [@20230103|5600862].  \n\n- Renal and hepatic function appear adequate for most systemic options, but full current labs and trends are unknown/needs update [@20221229|8300002].", "timestamp": "2026-01-18T18:37:28.215794"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Systemic regimen choice is impossible today without prior treatment history, performance status, and pathology details; these must be collected before committing to next-line therapy.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Given new bone and progressive visceral disease, please advise whether PET/CT adds actionable value over recent MR/CT for systemic-planning and potential local palliation decisions.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:37:52.582871"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:38:02.334479"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n[R1T2 DELTA] chair->oncologist(safety): Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe. | chair->radiologist(missing): Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT. | chair->pathologist(missing): Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Defer systemic treatment choice until updated post-12/2022 imaging (CT/MR and/or PET/CT) confirms current disease extent; prior reports unknown/needs update.  \n\n- Urgently retrieve and review original surgical/biopsy pathology with histology, grade, stage, and IHC to guide regimen selection; currently unknown.  \n\n- Compile full oncologic history (all prior surgeries, regimens, responses, toxicities, timing of relapse) and current ECOG, symptoms, and goals of care; unknown.  \n\n- Evaluate and manage severe anemia (Hgb 74 g/L) before/during any chemotherapy; complete iron/B12/folate/hemolysis/bleeding work-up and transfusion plan [@20230103|5600862].  \n\n- After data completion, define intent (palliation vs disease control) and choose appropriate next-line systemic category plus targeted/trial eligibility based on biomarkers [@OH2203828|2022-04-18].", "timestamp": "2026-01-18T18:38:13.051855"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:39:01.906554"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-18T18:39:12.472301"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n[R2T2 DELTA] chair->oncologist(safety): Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed. | chair->pathologist(missing): Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained. | oncologist->chair(safety): Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Defer commitment to specific regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed; histology currently unknown.  \n\n- Urgently obtain full pathology (primary site, subtype, grade, IHC) or arrange new biopsy if records unobtainable; currently missing.  \n\n- Acquire all post‑12/2022 imaging or arrange whole‑body PET/CT plus targeted CT/MR to restage disease and clarify rectal involvement; missing.  \n\n- Optimize severe anemia (Hgb 74 g/L) with full work‑up and transfusion/other support before systemic therapy decisions [@20230103|2023-01-03].  \n\n- In parallel, document prior treatments, ECOG, symptoms, comorbidities, and goals to define intent (disease control vs palliation) once data complete.", "timestamp": "2026-01-18T18:40:09.650041"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Presacral pelvic mass enlarged to 53×44 mm with heterogeneous signal and involvement of adjacent peritoneum and sacrum, suspicious recurrence.[@2022-12-29|MR]\n\n- New enhancing nodule in right ilium, concerning for osseous metastasis.[@2022-12-29|MR]\n\n- Multiple enhancing mesenteric/pelvic nodules unchanged, compatible with peritoneal metastases.[@2022-12-29|MR]\n\n- Focal rectal wall thickening with enhancement; needs correlation for invasion versus inflammatory change.[@2022-12-29|MR]\n\n- Liver with multiple new/enlarging hypodense lesions, consistent with progressive hepatic metastases; additional stable hepatic cysts and possible splenic infarct.[@2022-12-29|CT]", "timestamp": "2026-01-18T18:37:30.664958"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"No imaging newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:37:54.557247"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:38:03.804400"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n[R1T2 DELTA] chair->oncologist(safety): Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe. | chair->radiologist(missing): Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT. | chair->pathologist(missing): Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No imaging newer than 2022-12-29 MR/CT is available; updated whole-body FDG PET/CT restaging is required before planning.[@2022-12-29|MR][@2022-12-29|CT]\n\n- If PET/CT cannot fully characterize local anatomy, consider complementary pelvic MR or contrast CT to assess rectal and sacral involvement.[@2022-12-29|MR]\n\n- Radiology to confirm absence/presence of any post-12/2022 imaging and flag if interval complications (obstruction, fracture, thrombosis) are seen; currently unknown.\n\n- After new imaging, radiology will re-document measurable disease (presacral mass, liver, peritoneum, bone) to support response assessment and palliation planning.[@2022-12-29|MR][@2022-12-29|CT]\n\n- Until restaging completed, avoid definitive local procedures based solely on 12/2022 scans, given possible interval progression or new sites.[@2022-12-29|MR][@2022-12-29|CT]", "timestamp": "2026-01-18T18:38:20.980254"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:39:03.406174"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:39:36.934250"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n[R2T2 DELTA] chair->oncologist(safety): Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed. | chair->pathologist(missing): Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained. | oncologist->chair(safety): Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- 12/29/2022 MR: Presacral mass ~53×44 mm, invading adjacent peritoneum and sacrum; rectal wall thickening/enhancement suggests possible invasion.[@2022-12-29|MR]\n\n- 12/29/2022 MR: New enhancing nodule in right iliac bone, suspicious for osseous metastasis.[@2022-12-29|MR]\n\n- 12/29/2022 MR: Multiple enhancing pelvic mesenteric nodules compatible with peritoneal metastases.[@2022-12-29|MR]\n\n- 12/29/2022 CT: Multiple liver metastases, increased in number and size; largest ~17×14 mm.[@2022-12-29|CT]\n\n- No post-12/29/2022 imaging available; updated whole-body staging (PET/CT ± targeted MR/CT) is needed to guide current decisions.[@2022-12-29|MR][@2022-12-29|CT]", "timestamp": "2026-01-18T18:40:12.412043"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Only confirmed finding: germline ATM exon8 c.A947G:p.Y316C variant; clinical significance not specified in report [@OH2203828|2022-04-18].  \n- HRD reported negative; no pathogenic germline/somatic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 detected [@OH2203828|2022-04-18].  \n- Underlying tumor type, primary site, histologic subtype, grade, and stage are completely unknown/need update.  \n- No tumor tissue NGS, MSI/MMR, TMB, or other somatic profiling data available/needs update for integrated pathology assessment.  \n- Need full surgical pathology report(s) and any IHC panels to clarify diagnosis and guide biomarker interpretation.", "timestamp": "2026-01-18T18:37:33.424806"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:37:56.200349"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:38:05.125771"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n[R1T2 DELTA] chair->oncologist(safety): Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe. | chair->radiologist(missing): Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT. | chair->pathologist(missing): Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Retrieve and summarize original surgical/biopsy pathology, including primary site, histologic subtype, grade, and key IHC; currently unknown.  \n- Confirm and review any imaging after 12/2022; if absent, obtain whole‑body FDG PET/CT for up‑to‑date staging (bone, rectum, liver).  \n- Defer decisions on treatment line and intent until updated imaging and full pathology are available, per chair safety concern.  \n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) on available blocks once primary and subtype are confirmed; currently unknown.  \n- Reconvene MDT after completing pathology retrieval, updated staging, and basic lab/clinical status review (anemia work‑up, organ function, ECOG).", "timestamp": "2026-01-18T18:38:34.685815"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\",\"why\":\"safety\"}]}", "timestamp": "2026-01-18T18:39:05.387189"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:39:41.076754"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n[R2T2 DELTA] chair->oncologist(safety): Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed. | chair->pathologist(missing): Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained. | oncologist->chair(safety): Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Urgently obtain original surgical/biopsy pathology (reports and blocks) to confirm primary site, histologic subtype, grade, and stage; currently unknown.  \n- If outside pathology truly unobtainable, arrange new image‑guided biopsy of accessible lesion for full histology and IHC; currently unknown.  \n- With confirmed subtype, consider tumor profiling (MSI/MMR, TMB ± extended NGS) on available tissue for future options; currently unknown.  \n- Correlate pathology with updated cross‑sectional imaging or PET/CT to clarify rectal involvement and dominant disease sites; post‑12/2022 imaging unknown.  \n- Defer labeling line of therapy or specific systemic strategy until histology/subtype are established and MDT re‑reviews integrated findings.", "timestamp": "2026-01-18T18:40:15.345794"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No PET/CT or other nuclear imaging available for this visit; metabolic status of pelvic, hepatic, bone lesions unknown/needs update.  \n\n- Prior MR pelvis shows enlarging presacral mass with sacrum, peritoneum, right ilium involvement; recurrence/metastasis structurally suspected [@2022-12-29|MR].  \n\n- Prior CT abdomen shows multiple enlarging hepatic lesions consistent with metastases; PET would better characterize whole-body disease burden [@2022-12-29|CT].  \n\n- For current decision-making, a whole-body FDG PET/CT is needed to assess metabolic activity and refine staging/recurrence mapping.  \n\n- Cannot yet determine if PET would upstage or downstage compared with prior MR/CT; requires new PET/CT acquisition and report.", "timestamp": "2026-01-18T18:37:36.750926"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-18T18:37:58.362356"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:38:06.642048"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n[R1T2 DELTA] chair->oncologist(safety): Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe. | chair->radiologist(missing): Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT. | chair->pathologist(missing): Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Confirm and review any imaging newer than 12/29/2022; if absent, obtain updated contrast CT/MR plus whole-body FDG PET/CT [@2022-12-29|MR; @2022-12-29|CT].  \n- Use PET/CT to define metabolic extent of presacral mass, sacrum/ilium, peritoneum, liver, and possible rectal invasion [@2022-12-29|MR; @2022-12-29|CT].  \n- Retrieve complete original pathology (site, subtype, grade, IHC) to confirm primary ovarian origin and refine prognosis; currently unknown.  \n- Optimize anemia and overall medical status in parallel, ensuring patient is fit for subsequent systemic and/or locoregional interventions; lab details beyond Hgb unknown.  \n- Reconvene MDT after updated imaging and pathology to finalize staging, recurrence assessment, and integrate PET findings into overall management intent.", "timestamp": "2026-01-18T18:38:41.032868"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:39:06.809994"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-18T18:40:04.019101"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.\n[R2T1 DELTA] pathologist->chair(safety): Pathology remains completely unavailable; without confirmed primary site, histologic subtype, and grade, it is unsafe to finalize systemic strategy or trial eligibility discussions.\n[R2T2 DELTA] chair->oncologist(safety): Do not commit to a specific systemic regimen or line-of-therapy labelling until original/surgical pathology is retrieved and reviewed. | chair->pathologist(missing): Please urgently trace outside surgical/biopsy blocks/reports or arrange a new biopsy if prior pathology truly cannot be obtained. | oncologist->chair(safety): Agree it is unsafe to finalize systemic options without pathology; treatment discussion with patient should be framed as provisional pending histologic confirmation.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nIf you reference guideline/PubMed evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Arrange whole-body FDG PET/CT to update staging beyond 12/2022 CT/MR, including bone and rectal involvement assessment [@2022-12-29|MR; @2022-12-29|CT].  \n- Use PET/CT to confirm metabolic activity of presacral mass, sacral/iliac lesions, peritoneal nodules, and liver metastases [@2022-12-29|MR; @2022-12-29|CT].  \n- Correlate PET/CT with pelvic MR to better distinguish rectal invasion from inflammatory thickening before considering local interventions [@2022-12-29|MR].  \n- Integrate PET findings with tumor marker trends and future imaging for monitoring disease burden and response; current post-12/2022 imaging unknown.  \n- Re-discuss at MDT once PET/CT and pathology are available to align metabolic staging with final intent and palliation planning.", "timestamp": "2026-01-18T18:40:18.080007"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Advanced recurrent ovarian malignancy with progressive pelvic mass, pelvic bone lesion, and liver metastases on recent imaging [@2022-12-29|MR; @2022-12-29|CT].  \\n- HRD-/BRCA‑wildtype; systemic therapy plan should not assume PARP benefit outside trial; consider standard chemotherapy-based approach [@OH2203828].  \\n- Profound anemia (HGB 74 g/L) likely requires optimization and transfusion planning before intensive systemic therapy [@20230103|2023-01-03].  \\n- Tumor markers very elevated (CA125, CA19-9, CA15-3); can be used for response monitoring, not for standalone decisions [@20221229|9703212].  \\n- Missing: current histology/grade, prior surgery/chemo details, performance status, symptoms, patient goals—must be updated before definitive systemic/locoregional plan.\",\"oncologist\":\"- Tumor type, stage, prior surgery/chemotherapy, and current disease status are unknown/needs update to define treatment line and intent.  \\n\\n- Markedly elevated CA125, CA19-9, CA15-3 and ROMA suggest ovarian malignancy, but histology/pathology report is unknown/needs update [@20221229|9703212].  \\n\\n- HRD negative and no BRCA1/2 pathogenic variants; this limits certain maintenance options after platinum response [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|18].  \\n\\n- Significant anemia (Hgb 74 g/L) requires evaluation of cause and correction before or during systemic therapy [@20230103|5600862].  \\n\\n- Renal and hepatic function appear adequate for most systemic options, but full current labs and trends are unknown/needs update [@20221229|8300002].\",\"radiologist\":\"- Presacral pelvic mass enlarged to 53×44 mm with heterogeneous signal and involvement of adjacent peritoneum and sacrum, suspicious recurrence.[@2022-12-29|MR]\\n\\n- New enhancing nodule in right ilium, concerning for osseous metastasis.[@2022-12-29|MR]\\n\\n- Multiple enhancing mesenteric/pelvic nodules unchanged, compatible with peritoneal metastases.[@2022-12-29|MR]\\n\\n- Focal rectal wall thickening with enhancement; needs correlation for invasion versus inflammatory change.[@2022-12-29|MR]\\n\\n- Liver with multiple new/enlarging hypodense lesions, consistent with progressive hepatic metastases; additional stable hepatic cysts and possible splenic infarct.[@2022-12-29|CT]\",\"pathologist\":\"- Only confirmed finding: germline ATM exon8 c.A947G:p.Y316C variant; clinical significance not specified in report [@OH2203828|2022-04-18].  \\n- HRD reported negative; no pathogenic germline/somatic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 detected [@OH2203828|2022-04-18].  \\n- Underlying tumor type, primary site, histologic subtype, grade, and stage are completely unknown/need update.  \\n- No tumor tissue NGS, MSI/MMR, TMB, or other somatic profiling data available/needs update for integrated pathology assessment.  \\n- Need full surgical pathology report(s) and any IHC panels to clarify diagnosis and guide biomarker interpretation.\",\"nuclear\":\"- No PET/CT or other nuclear imaging available for this visit; metabolic status of pelvic, hepatic, bone lesions unknown/needs update.  \\n\\n- Prior MR pelvis shows enlarging presacral mass with sacrum, peritoneum, right ilium involvement; recurrence/metastasis structurally suspected [@2022-12-29|MR].  \\n\\n- Prior CT abdomen shows multiple enlarging hepatic lesions consistent with metastases; PET would better characterize whole-body disease burden [@2022-12-29|CT].  \\n\\n- For current decision-making, a whole-body FDG PET/CT is needed to assess metabolic activity and refine staging/recurrence mapping.  \\n\\n- Cannot yet determine if PET would upstage or downstage compared with prior MR/CT; requires new PET/CT acquisition and report.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral pelvic mass (sacral/peritoneal involvement), new right iliac bone lesion, multiple peritoneal nodules, and progressive liver metastases on MR/CT (12/2022).\n- HRD negative, BRCA-wildtype; no actionable germline BRCA/HRR alterations identified. ATM variant of uncertain/unspecified significance.\n- Profound anemia (Hgb ~74 g/L) requiring optimization before or during systemic therapy.\n- Renal/hepatic function currently appear adequate for standard chemotherapy; tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring only.\n\nControversies:\n- Exact line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and performance status.\n- Histologic subtype and grade unknown, limiting precision of systemic/targeted options and trial matching.\n- Extent of rectal wall involvement and clinical relevance (local symptoms, need for local palliation) uncertain.\n- Role/timing of PET/CT for restaging versus proceeding based on current MR/CT alone.\n\nMissing Info:\n- Definitive pathology: primary site confirmation, histologic subtype, grade, staging; any IHC; prior surgical pathology reports.\n- Full oncologic history: prior surgeries, chemotherapy regimens, responses, toxicities, maintenance treatments, and timing of relapse.\n- Current clinical status: ECOG performance status, symptom burden (pain, bleeding, bowel/bladder function), weight, comorbidities, and patient goals/preferences.\n- Updated labs: current CBC (trend of anemia), renal/hepatic function, coagulation, and cause/management plan for anemia.\n- Any prior somatic tumor profiling (NGS, MSI/MMR, TMB, PD-L1) and prior imaging after 12/2022 if available.\n\nWorking Plan:\n- Clarify oncologic history, current pathology, performance status, and patient goals before defining treatment line and intent.\n- Correct/evaluate anemia and optimize medical status in parallel with staging work-up.\n- Consider comprehensive restaging, including whole-body FDG PET/CT, to refine disease burden (bone, liver, pelvic/rectal involvement).\n- Obtain or repeat tumor tissue profiling (including MSI/MMR, TMB +/- extended NGS) if feasible for future systemic and trial options.\n- After above information is available, MDT to reconvene to outline systemic therapy strategy (likely chemotherapy-based), and assess need for any locoregional palliation (pelvic mass, bone lesion, rectal involvement).", "timestamp": "2026-01-18T18:37:43.297292"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral pelvic mass (sacral/peritoneal involvement), new right iliac bone lesion, multiple peritoneal nodules, and progressive liver metastases on MR/CT (12/2022).\n- HRD negative, BRCA-wildtype; no actionable germline BRCA/HRR alterations identified. ATM variant of uncertain/unspecified significance.\n- Profound anemia (Hgb ~74 g/L) requiring optimization before or during systemic therapy.\n- Renal/hepatic function currently appear adequate for standard chemotherapy; tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring only.\n\nControversies:\n- Exact line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and performance status.\n- Histologic subtype and grade unknown, limiting precision of systemic/targeted options and trial matching.\n- Extent of rectal wall involvement and clinical relevance (local symptoms, need for local palliation) uncertain.\n- Role/timing of PET/CT for restaging versus proceeding based on current MR/CT alone.\n\nMissing Info:\n- Definitive pathology: primary site confirmation, histologic subtype, grade, staging; any IHC; prior surgical pathology reports.\n- Full oncologic history: prior surgeries, chemotherapy regimens, responses, toxicities, maintenance treatments, and timing of relapse.\n- Current clinical status: ECOG performance status, symptom burden (pain, bleeding, bowel/bladder function), weight, comorbidities, and patient goals/preferences.\n- Updated labs: current CBC (trend of anemia), renal/hepatic function, coagulation, and cause/management plan for anemia.\n- Any prior somatic tumor profiling (NGS, MSI/MMR, TMB, PD-L1) and prior imaging after 12/2022 if available.\n\nWorking Plan:\n- Clarify oncologic history, current pathology, performance status, and patient goals before defining treatment line and intent.\n- Correct/evaluate anemia and optimize medical status in parallel with staging work-up.\n- Consider comprehensive restaging, including whole-body FDG PET/CT, to refine disease burden (bone, liver, pelvic/rectal involvement).\n- Obtain or repeat tumor tissue profiling (including MSI/MMR, TMB +/- extended NGS) if feasible for future systemic and trial options.\n- After above information is available, MDT to reconvene to outline systemic therapy strategy (likely chemotherapy-based), and assess need for any locoregional palliation (pelvic mass, bone lesion, rectal involvement).\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).", "timestamp": "2026-01-18T18:37:47.930654"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal nodules, and progressive liver metastases (12/2022 MR/CT).\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) needing optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) very elevated; suitable for monitoring only.\n\nControversies:\n- Line of therapy and intent (palliative vs disease-controlling) unclear without prior treatment history and PS.\n- Histologic subtype/grade unknown, limiting targeted/trial options.\n- Significance of rectal wall involvement (true invasion vs inflammation; need for local palliation) uncertain.\n- Whether to proceed on current MR/CT vs obtain PET/CT for restaging first.\n\nMissing Info:\n- Full pathology: primary site confirmation, histology, grade, stage, IHC, prior surgical pathology.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs (CBC trends, renal/hepatic, coagulation) and anemia work-up/plan.\n- Any prior somatic profiling (NGS, MSI/MMR, TMB, PD-L1) and imaging after 12/2022.\n\nWorking Plan:\n- Obtain/clarify pathology, oncologic history, current performance status, and patient goals to define intent and line of therapy.\n- Investigate and correct anemia; optimize overall medical status.\n- Perform comprehensive restaging, ideally whole-body FDG PET/CT, to map full disease burden (including bone and rectal involvement).\n- Arrange tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible for future options/trials.\n- Reconvene MDT after data completion to define systemic strategy and any locoregional palliation needs (pelvic mass, bone, rectal involvement).\n[R1T1 DELTA] newer than 12/29/2022 is available; updated cross‑sectional imaging or PET/CT is needed before current treatment decisions. | radiologist->nuclear(missing): If clinically appropriate, a whole‑body FDG PET/CT would better define current disease extent, especially bone and rectal involvement. | pathologist->chair(missing): Pathology for this ovarian malignancy is entirely absent in the record; we need original surgical/biopsy reports and IHC to confirm primary, subtype, and grade. | nuclear->oncologist(missing): Given suspected pelvic, hepatic, peritoneal, and new bone involvement, a whole-body FDG PET/CT would refine staging and recurrence mapping before finalizing systemic or local palliation plans. | nuclear->radiologist(missing): Please consider PET/CT to clarify metabolic activity and true extent of presacral mass, right iliac lesion, liver metastases, and possible rectal involvement.\n[R1T2 DELTA] chair->oncologist(safety): Management planning should wait for updated imaging and retrieval of original pathology; without these, defining intent and line of therapy is unsafe. | chair->radiologist(missing): Please confirm if any post-12/29/2022 imaging exists and whether additional CT/MR is still needed alongside planned PET/CT. | chair->pathologist(missing): Kindly prioritize obtaining and summarizing the original surgical/biopsy pathology with subtype and grade so systemic strategy is appropriately tailored.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Progressive advanced ovarian malignancy with enlarging presacral mass (sacrum/peritoneum), new right iliac bone lesion, peritoneal disease, and liver metastases on 12/2022 MR/CT.\n- HRD negative, BRCA-wildtype; ATM variant of uncertain significance; no known actionable HRR mutation.\n- Marked anemia (Hgb ~74 g/L) requiring optimization; renal/hepatic function likely adequate for chemotherapy.\n- Tumor markers (CA125, CA19-9, CA15-3) markedly elevated and suitable for monitoring.\n- Newer imaging than 12/29/2022 is referenced but not available; current decisions need truly up‑to‑date staging.\n\nControversies:\n- Line of therapy and overall intent (palliative vs disease-controlling) cannot be safely defined without prior treatment history, performance status, and updated imaging.\n- Histologic subtype/grade unknown, limiting precision of systemic strategy and trial eligibility.\n- Clinical significance of rectal wall changes (true invasion vs inflammation; need for local palliation) remains uncertain.\n- Extent to which PET/CT vs additional CT/MR should guide restaging and planning.\n\nMissing Info:\n- Original and any subsequent pathology: primary site confirmation, histologic subtype, grade, stage, IHC, full surgical/biopsy reports.\n- Detailed oncologic history: surgeries, systemic regimens, responses, toxicities, timing/pattern of relapse.\n- Current clinical status: ECOG, symptom burden (pain, bowel/bladder, bleeding), weight, comorbidities, patient goals.\n- Updated labs: CBC trends, renal/hepatic function, coagulation, and anemia work-up/plan.\n- All imaging after 12/29/2022, including any CT/MR and any PET/CT if already performed.\n- Tumor somatic profiling (NGS, MSI/MMR, TMB, PD-L1), if ever done.\n\nWorking Plan:\n- Prioritize retrieval and summary of original surgical/biopsy pathology (including subtype and grade).\n- Confirm and collect all post‑12/2022 imaging; if not done, arrange comprehensive restaging with whole‑body FDG PET/CT and radiology review (including bone and rectal involvement).\n- Clarify full oncologic history, current ECOG status, symptom burden, comorbidities, and patient preferences/goals.\n- Evaluate and correct anemia; optimize medical status in parallel with staging.\n- Obtain or repeat tumor tissue profiling (MSI/MMR, TMB ± extended NGS) if feasible.\n- Defer systemic/locoregional treatment planning until updated imaging and pathology are available, then reconvene MDT to define intent, line of therapy, and any required local palliation.", "timestamp": "2026-01-18T18:38:58.733196"}]}, "trace_events": [{"ts": "2026-01-18T18:36:45.962501", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-18T18:36:45.962785", "event": "case_fingerprint", "payload": {"case_fingerprint": "bf21a9e8fbc5"}}, {"ts": "2026-01-18T18:36:46.218777", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-18T18:36:56.242652", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|MR|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-18T18:37:14.417671", "event": "rag_query", "payload": {"query": "Guidelines for management of ovarian cancer by histology and platinum sensitivity, considering typical metastatic spread and extent of disease, relevant biomarkers (BRCA/HRD/MSI/PD-L1/ATM), and treatment selection with constraints such as anemia, organ dysfunction, and performance status."}}, {"ts": "2026-01-18T18:37:14.417701", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-18T18:37:14.417708", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-18T18:37:14.417713", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-18T18:37:22.351520", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-18T18:37:25.366171", "event": "evidence_tag_warning", "payload": {"role": "chair/initial", "preview": "- Advanced recurrent ovarian malignancy with progressive pelvic mass, pelvic bone lesion, and liver metastases on recent imaging [@2022-12-29|MR; @2022-12-29|CT…"}}, {"ts": "2026-01-18T18:37:28.215965", "event": "evidence_tag_warning", "payload": {"role": "oncologist/initial", "preview": "- Tumor type, stage, prior surgery/chemotherapy, and current disease status are unknown/needs update to define treatment line and intent.    - Markedly elevated…"}}, {"ts": "2026-01-18T18:38:09.860625", "event": "evidence_tag_warning", "payload": {"role": "chair/final_round_1", "preview": "- Defer definitive systemic/locoregional plan until original pathology (subtype, grade, IHC) is obtained and reviewed [@OH2203828].   - Arrange whole-body FDG P…"}}, {"ts": "2026-01-18T18:38:13.051924", "event": "evidence_tag_warning", "payload": {"role": "oncologist/final_round_1", "preview": "- Defer systemic treatment choice until updated post-12/2022 imaging (CT/MR and/or PET/CT) confirms current disease extent; prior reports unknown/needs update. …"}}, {"ts": "2026-01-18T18:40:06.811325", "event": "evidence_tag_warning", "payload": {"role": "chair/final_round_2", "preview": "- Urgently retrieve prior pathology or arrange new biopsy to establish primary site, histologic subtype, and grade (currently unknown).   - Obtain all post‑12/2…"}}, {"ts": "2026-01-18T18:40:18.080117", "event": "mdt_discussion_end", "payload": {"merged_chars": 3260}}, {"ts": "2026-01-18T18:40:18.080956", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-18T18:40:21.879150", "event": "final_output_end", "payload": {"final_output_chars": 1500}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
